Drugs / Umbilical Cord Lining Stem Cells (ULSC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04494386 | Dec 2020 → May 2023 | COVID-19, acute respiratory distress syndrome | Restem, LLC. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Lining Stem Cells (ULSC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04494386 ↗ |
| Route | Intravenous | “IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection” NCT04494386 ↗ |